Intravitreal Injection of Ultevursen

DRUG2 trials

Sponsors

Laboratoires Thea

Conditions

Deaf BlindEye Diseases, HereditaryEye Disorders CongenitalRetinal DiseaseRetinitis Pigmentosa (RP)Usher Syndrome Type 2Vision Disorders

Phase 2

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Active, not recruitingNCT06627179

Laboratoires TheaDeaf Blind, Eye Diseases, Hereditary, Eye Disorders Congenital +4

Start: 2024-12-11End: 2028-07-01Target: 81Updated: 2026-07-09

Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Not yet recruitingNCT07796646

Laboratoires TheaDeaf Blind, Eye Diseases, Hereditary, Eye Disorders Congenital +4

Start: 2026-10-05End: 2030-03-01Target: 81Updated: 2026-09-01